Lupituss Oral Suspension contains Levocloperastine at a concentration of 20 mg per 5 ml and is indicated for the symptomatic relief of dry cough associated with upper respiratory tract infections and other non-productive cough conditions. Levocloperastine is a non-opioid antitussive agent that acts centrally on the cough center in the medulla oblongata, effectively suppressing the cough reflex without causing sedation or respiratory depression. This medication is suitable for both adults and children, providing rapid and sustained cough suppression to improve patient comfort and quality of life. Lupituss Oral Suspension is formulated for ease of administration and accurate dosing, ensuring optimal therapeutic outcomes. It is generally well tolerated, with a low incidence of adverse effects; however, patients should be advised to avoid concurrent use with other central nervous system depressants unless directed by a healthcare professional. Caution is recommended in individuals with known hypersensitivity to Levocloperastine or any excipients in the formulation. As with all antitussives, it is important to use Lupituss Oral Suspension only for the duration prescribed and to seek medical advice if symptoms persist beyond one week or are accompanied by fever, rash, or persistent headache, which may indicate a more serious underlying condition.